Cantourage Group SE Reports Strong Third Quarter EBITDA Growth

In the third quarter of 2024, Cantourage Group SE reached an EBITDA of EUR 1.4 million, marking significant growth from EUR -0.7 million in Q3 2023. This achievement is backed by increased sales, which rose to EUR 30.2 million from January to September 2024, compared to EUR 17.0 million in the prior-year period.

The company's strategy involves expanding processing capabilities in Germany and Portugal, influenced significantly by partial legalization of cannabis. This has enabled Cantourage to address the growing demand in Germany and the UK. Their portfolio has been enriched with 16 new cannabis strains, contributing to their growth in the European medical cannabis market.

Analysts from NuWays and Montega endorse Cantourage shares, setting price targets at EUR 10.00 and EUR 11.00 respectively. With plans to introduce the "value" brand MEDICUS, Cantourage positions itself for continued strong growth.